CN117843766A - 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 - Google Patents
高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 Download PDFInfo
- Publication number
- CN117843766A CN117843766A CN202310607996.1A CN202310607996A CN117843766A CN 117843766 A CN117843766 A CN 117843766A CN 202310607996 A CN202310607996 A CN 202310607996A CN 117843766 A CN117843766 A CN 117843766A
- Authority
- CN
- China
- Prior art keywords
- scfv
- infectious bursal
- bursal disease
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000702626 Infectious bursal disease virus Species 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 241000287828 Gallus gallus Species 0.000 claims description 11
- 235000013330 chicken meat Nutrition 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 230000002458 infectious effect Effects 0.000 claims description 9
- 208000027312 Bursal disease Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 3
- 102000053602 DNA Human genes 0.000 claims description 3
- 230000009261 transgenic effect Effects 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000002965 ELISA Methods 0.000 abstract description 12
- 238000001514 detection method Methods 0.000 abstract description 5
- 238000002819 bacterial display Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 101500001532 Avian infectious bursal disease virus Capsid protein VP2 Proteins 0.000 abstract description 2
- 230000004186 co-expression Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000006386 neutralization reaction Methods 0.000 abstract description 2
- 244000052769 pathogen Species 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 17
- 239000000872 buffer Substances 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000012460 protein solution Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241001260012 Bursa Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920004449 Halon® Polymers 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
本发明公开了高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用。本发明提供的scFv抗体，包括由重链可变区、轻链可变区以及它们之间的连接区组成；本发明利用抗原‑抗体共表达的细菌展示技术筛选获得了8株scFv抗体，并且与IBDV VP2蛋白和不同的IBDV病毒株具有高亲和力，其可以通过构建突变库筛选出具有高亲和力和中和活性的scFv抗体，用于防治IBD；其也可以用于ELISA法检测IBDV病原。
Description
技术领域
本发明涉及高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用，属于生物技术领域。
背景技术
鸡传染性法氏囊病(Infectious Bursal Disease，IBD)是由鸡传染性法氏囊病毒(Infectious Bursal Disease Virus，IBDV)引起的一种急性、高度接触性传染病，IBDV主要侵害3-12周龄的雏鸡和青年鸡，损伤鸡的中枢免疫器官——法氏囊。具有传播速度快、传染性强、感染率及死亡率均高的特点。该病目前在全球范围内均有分布，是养禽业最重要疾病之一，并且因免疫失败而造成的经济损失巨大。
IBDV可在雏鸡法氏囊中的淋巴细胞，尤其是B淋巴细胞中迅速繁殖，导致免疫抑制,从而可增强机体对其它病原体的易感性并且降低对其它疫苗的反应性。抗体药物目前是有效的治疗药物，高免血清和卵黄抗体在发病早期均可起到良好的效果，但是由于工业化生产可控性差和存在水平传播疾病等原因而受到限制。本发明利用抗原-抗体共表达的细菌展示技术筛选获得了8株具有较高亲和力的抗IBDV的scFv抗体，其可以通过构建突变库筛选出具有高亲和力和中和活性的scFv抗体，用于防治IBD；其也可以用于双抗夹心ELISA法检测病原IBDV的存在。
发明内容
本发明的目的是提供高亲和力的抗鸡传染性法氏囊病毒的scFv抗体及其应用。scFv抗体是由重链可变区、轻链可变区以及它们之间的连接区组成，它们能够与IBDV VP2蛋白高亲和力结合，在治疗或者预防传染性法氏囊病和检测传染性法氏囊病毒的ELISA试剂盒中具有重要应用。
附图说明
图1为scFv抗体的SDS-PAGE图谱。
图2为ELISA检测scFv抗体对VP2蛋白的特异性和亲和力的结果。
图3为ELISA检测scFv抗体对不同IBDV病毒的特异性和亲和力的结果。
具体实施方式
以下的实施例便于更好地理解本发明，但并不限定本发明。下述实施例中的实验方法，如无特殊说明，均为常规方法。下述实施例中所用的试验材料，如无特殊说明，均为自常规生化试剂商店购买得到的。以下实施例中的定量试验，均设置三次重复实验，结果取平均值。
pET-27b(+)载体：购自Novagen公司，Cat.No.69337-3。大肠杆菌Rosetta：购自Novagen公司，Cat.No.71403-4。鸡传染性法氏囊病活疫苗(Gt株)：哈兽研维科生物公司，编号080012122。鸡传染性法氏囊病中等毒力活疫苗(NF8株)：扬州威克生物工程有限公司，编号101042056。鸡传染性法氏囊病活疫苗(MB株)：ABIC，编号20621150B。鸡传染性法氏囊病活疫苗(B87株)：湖南省中岸生物药业有限公司，编号180022026。
包被液(pH9.6)：取Na2CO3 0.15g、NaHCO3 0.293g，溶于水并用水定容至100mL。
PBS缓冲液：取NaCl 8g、KCl 0.2g、Na2HPO4.12H2O 3.58g、KH2PO4 0.24g，溶于1L水。
实施例1、scFv抗体及其编码基因的获得
1、抗体库的构建
取IBDV免疫后的鸡脾脏，提取RNA后反转录成cDNA。根据GenBank上的抗体序列，设计出克隆抗体可变区的基因引物，以cDNA为模板，使用PCR的方法克隆抗体可变区基因。将VH与VL片段连接成scFv基因并与细菌展示载体pBFD-Ab-VP2进行连接，构建抗IBDV抗原抗体共表达的细菌表面展示文库。VH约380bp、VL约320bp，VH-Tlinker-VL约740bp。
2、抗体库的筛选
收集转化后全部克隆，经IPTG(0.25mmol/L)诱导4h，经EDTA-MgCl2处理，与兔抗VP2蛋白的多克隆抗体(即实施例4制备的多克隆抗体溶液，工作浓度为1:5 000倍稀释)及FITC标记的羊抗兔二抗(购自sigma公司，工作浓度为1:500倍稀释)各孵育1h，PBS洗涤后利用流式细胞仪对其进行筛选。
经三轮筛选后得到8个与VP2蛋白具有高结合能力的scFv单克隆抗体，将其分别命名为scFv-11、scFv-12、scFv-13、scFv-14、scFv-15、scFv-16、scFv-17和scFv-18抗体。
8种scFv抗体的氨基酸序列如序列表的序列1～8所示，其核苷酸序列如序列表的序列9～16所示。
实施例2、8种scFv抗体的制备
1、以实施例1中筛选获得的能够表达8个具有高结合能力的单克隆抗体的质粒为模板，用F1和R1组成的引物分别对8个scFv抗体基因进行PCR扩增，得到PCR扩增产物。
F1：5'–CGCCATATGGCCGTGACGTTGGACGAG-3'；
R1：5'–CCCAAGCTTTTAACCTAGGACGGTCAGGG-3'。
2、用限制性内切酶Nde I和Hind III双酶切步骤1的PCR扩增产物，回收酶切产物。
3、用限制性内切酶Nde I和Hind III双酶切pET-27b(+)载体，回收约5367bp的载体骨架。
4、将步骤2的酶切产物和步骤3的载体骨架连接，得到重组质粒。根据测序结果，对重组质粒进行结构描述如下：在pET-27b(+)载体的Nde I和Hind III酶切位点之间插入了序列表的序列9～16所示的双链DNA分子。
5、将步骤4得到的重组质粒导入大肠杆菌Rosetta，得到重组菌。
6、将步骤5得到的重组菌接种至含50μg/ml卡那霉素的LB液体培养基，37℃、100r/min振荡培养至OD600nm＝0.3；加入IPTG并使其浓度为0.25mmol/L，37℃、100r/min振荡培养4h。
7、取15L完成步骤6的培养体系，4℃、4000r/min离心30min并收集菌体沉淀。
8、取步骤7得到的菌体沉淀，用PBS缓冲液重悬，加入溶菌酶溶液(购自Amresco)并使溶菌酶的浓度为1mg/ml，4℃放置1h，然后进行超声破碎(25瓦的功率，3min)，4℃、10000g离心30min，收集沉淀。
9、使用AKTA Purifier 100蛋白层析系统(购自GE公司)纯化目的蛋白
取步骤8得到的沉淀，用100毫升溶解缓冲液(8mol/L尿素水溶液，pH8.0)充分溶解，然后上样于HiLoad 16/60Superdex75 pg柱子(购自GE公司)，然后用500mL复性缓冲液(2mol/L尿素水溶液，pH8.0)洗脱并收集过柱后的洗脱液，然后在PBS缓冲液中透析过夜，得到溶液即为8个scFv抗体溶液。所有步骤均在4℃环境下。8种scFv抗体溶液的SDS-PAGE图谱见图1，显示约为28kD的条带，与预期相符。
实施例3、ELISA检测scFv抗体的亲和力和特异性
一、ELISA检测几种scFv抗体对VP2蛋白的特异性和亲和力
1、用蛋白浓度为10μg/ml的scFv抗体溶液(即实施例2制备的scFv抗体溶液，用包被液调整蛋白浓度)包被酶标板，4℃过夜，然后用PBST缓冲液洗涤3次，每次2min。
2、每孔加入100μl蛋白浓度为40μg/ml的VP2蛋白溶液，37℃孵育1h，然后用PBST缓冲液洗涤3次，每次2min。
3、加入兔抗VP2多克隆抗体，37℃孵育1h，然后用PBST缓冲液洗涤3次，每次2min。
4、加入HRP标记的羊抗兔抗体(购自R&D system公司，工作浓度为1:8 000倍稀释)，37℃孵育1h，然后用PBST缓冲液洗涤3次，每次2min。
5、加入TMB底物显色液，37℃避光显色5min。
6、每孔加入50μl 2mol/L的H2SO4水溶液，用酶标仪于波长450nm下检测OD值。
设置用等体积的PBS缓冲液代替步骤2中的VP2蛋白溶液和步骤3中的兔抗VP2多克隆抗体的PBS组。步骤1中用蛋白浓度为10μg/ml的scFv抗体溶液包被酶标板时：设置步骤2中不加入VP2蛋白溶液的对照组1，步骤3中不加入兔抗VP2多克隆抗体的对照组2，步骤2中不加入VP2蛋白溶液且步骤3中不加入兔抗VP2多克隆抗体的对照组3，用等体积且等蛋白浓度的BSA溶液代替VP2蛋白溶液的对照组4。
每个处理设置3个复孔。
结果见图2。ELISA结果表明，8种scFv抗体均可以与VP2蛋白特异性结合，具有高亲和力。
二、ELISA检测scFv抗体对不同IBDV病毒的特异性和亲和力
1、用蛋白浓度为10μg/ml的scFv抗体溶液(即实施例2制备的scFv抗体溶液，用包被液调整蛋白浓度)包被酶标板，4℃过夜，然后用PBST缓冲液洗涤3次，每次2min。
2、每孔加入100μl IBDV病毒液(病毒剂量为106.2TCID50)，37℃孵育1h，然后用PBST缓冲液洗涤3次，每次2min。
3、加入兔抗VP2多克隆抗体，37℃孵育1h，然后用PBST缓冲液洗涤3次，每次2min。
4、加入HRP标记的羊抗兔抗体(购自R&D system公司，工作浓度为1:8 000倍稀释)，37℃孵育1h，然后用PBST缓冲液洗涤3次，每次2min。
5、加入TMB底物显色液，37℃避光显色5min。
6、每孔加入50μl 2mol/L的H2SO4水溶液，用酶标仪于波长450nm下检测OD值。
分别采用如下IBDV的毒株进行上述实验：Gt株、NF8株、MB株、B87株。
设置用等体积的PBS缓冲液代替步骤2中的IBDV病毒液和步骤3中的兔抗VP2多克隆抗体的PBS组。设置步骤2中不加入IBDV病毒液的对照组1，步骤3中不加入兔抗VP2多克隆抗体的对照组2，步骤2中不加入IBDV病毒液且步骤3中不加入兔抗VP2多克隆抗体的对照组3，用等体积等滴度的新城疫病毒液代替IBDV病毒液的对照组4。
每个处理设置3个复孔。
结果见图3。ELISA结果表明，8种scFv抗体均可以与不同IBDV毒株特异性结合，对不同的IBDV毒株具有不同的亲和力。
Claims (5)
1.一种抗鸡传染性法氏囊病毒的单链抗体scFv-15，单链抗体由重链可变区、轻链可变区以及它们之间的连接区组成；
所述scFv-15为如下(a)：(a)由序列表中序列5自N末端第1-245位氨基酸残基组成的蛋白质。
2.编码权利要求1所述单链抗体的基因。
3.如权利要求2所述的基因，其特征在于：
所述基因中，编码所述scFv-15的DNA分子为如下(1)：(1)序列表的序列13自5’末端第1-738位核苷酸所示的DNA分子。
4.含有权利要求2至3中任一所述基因的表达盒、重组载体、转基因细胞系或重组菌。
5.根据权利要求1所述的单链抗体，权利要求2或3所述的基因，或权利要求4所述的表达盒、重组载体、转基因细胞系或重组菌在制备产品中的应用；所述产品的功能为如下(Ⅰ)和/或(Ⅱ)和/或(Ⅲ)和/或(Ⅳ)：(Ⅰ)检测鸡传染性法氏囊病病毒；(Ⅱ)辅助鉴定鸡传染性法氏囊病病毒；(Ⅲ)预防和/或治疗鸡传染性法氏囊病；(Ⅳ)预防和/或治疗由鸡传染性法氏囊病病毒诱发的疾病。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310607996.1A CN117843766B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111522402.4A CN114213532B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202310607996.1A CN117843766B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111522402.4A Division CN114213532B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117843766A true CN117843766A (zh) | 2024-04-09 |
| CN117843766B CN117843766B (zh) | 2024-09-03 |
Family
ID=80701608
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310608003.2A Active CN117843771B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202310608002.8A Active CN117843770B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202310607998.0A Active CN117843767B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202310607999.5A Active CN117843768B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202310608000.9A Active CN117843769B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202310607996.1A Active CN117843766B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202310608001.3A Pending CN118240070A (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202111522402.4A Active CN114213532B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310608003.2A Active CN117843771B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202310608002.8A Active CN117843770B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202310607998.0A Active CN117843767B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202310607999.5A Active CN117843768B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202310608000.9A Active CN117843769B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310608001.3A Pending CN118240070A (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
| CN202111522402.4A Active CN114213532B (zh) | 2021-12-13 | 2021-12-13 | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (8) | CN117843771B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113493509B (zh) * | 2021-07-23 | 2023-04-28 | 东北农业大学 | 抗鸡传染性法氏囊病毒的四价高亲和力抗体及其制备和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103333242A (zh) * | 2013-07-23 | 2013-10-02 | 哈尔滨博翱生物医药技术开发有限公司 | scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用 |
| CN103483449A (zh) * | 2013-08-20 | 2014-01-01 | 东北农业大学 | 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用 |
| US20200165630A1 (en) * | 2016-04-29 | 2020-05-28 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR546801A0 (en) * | 2001-06-05 | 2001-06-28 | Commonwealth Scientific And Industrial Research Organisation | Recombinant antibodies |
| US10077316B2 (en) * | 2013-12-27 | 2018-09-18 | National University Corporation, Kochi University | Esophageal cancer marker and use thereof |
| CN105384815B (zh) * | 2015-12-03 | 2019-03-01 | 江苏康缘瑞翱生物医药科技有限公司 | 一种scFv抗体在治疗或预防鸡传染性法氏囊病制剂中的应用 |
| CN108484759A (zh) * | 2018-03-01 | 2018-09-04 | 东北农业大学 | 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用 |
| CN110878123B (zh) * | 2018-09-05 | 2022-08-23 | 华瑞同康生物技术（深圳）有限公司 | 一种抗tk1原核重组单链抗体及制备方法 |
-
2021
- 2021-12-13 CN CN202310608003.2A patent/CN117843771B/zh active Active
- 2021-12-13 CN CN202310608002.8A patent/CN117843770B/zh active Active
- 2021-12-13 CN CN202310607998.0A patent/CN117843767B/zh active Active
- 2021-12-13 CN CN202310607999.5A patent/CN117843768B/zh active Active
- 2021-12-13 CN CN202310608000.9A patent/CN117843769B/zh active Active
- 2021-12-13 CN CN202310607996.1A patent/CN117843766B/zh active Active
- 2021-12-13 CN CN202310608001.3A patent/CN118240070A/zh active Pending
- 2021-12-13 CN CN202111522402.4A patent/CN114213532B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103333242A (zh) * | 2013-07-23 | 2013-10-02 | 哈尔滨博翱生物医药技术开发有限公司 | scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用 |
| CN103483449A (zh) * | 2013-08-20 | 2014-01-01 | 东北农业大学 | 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用 |
| US20200165630A1 (en) * | 2016-04-29 | 2020-05-28 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
Non-Patent Citations (5)
| Title |
|---|
| LI, T.等: ""immunoglobulin single chain variable fragment, partial [synthetic construct]"", 《GENBANK》, 24 July 2013 (2013-07-24), pages 50943 * |
| XIAOCHEN GUO 等: ""Screening scFv antibodies against infectious bursal disease virus by co-expression of antigen and antibody in the bacteria display system"", 《VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY》, vol. 180, 9 September 2016 (2016-09-09), pages 45 - 52, XP029750459, DOI: 10.1016/j.vetimm.2016.09.004 * |
| YINGJIE ZHANG 等: ""A recombinant avian antibody against VP2 of infectious bursal disease virus protects chicken from viral infection"", 《RES VET SCI》, vol. 114, 8 April 2017 (2017-04-08), pages 194 - 201, XP085223391, DOI: 10.1016/j.rvsc.2017.04.003 * |
| 周兵 等: ""抗鸡传染性法 氏囊病病毒单链抗体库 的构建及其中和抗体的 筛选"", 《中国预防兽医学报》, vol. 36, no. 3, 31 March 2014 (2014-03-31), pages 227 - 231 * |
| 张瑛杰 等: ""抗鸡传染性 法氏囊病病毒抗体Fab 的 表达及其中和活性的测定"", 《中国预防兽医学报》, vol. 37, no. 11, 30 November 2015 (2015-11-30), pages 866 - 870 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117843768B (zh) | 2024-08-20 |
| CN117843769A (zh) | 2024-04-09 |
| CN117843770B (zh) | 2024-09-03 |
| CN117843766B (zh) | 2024-09-03 |
| CN117843770A (zh) | 2024-04-09 |
| CN117843771A (zh) | 2024-04-09 |
| CN118240070A (zh) | 2024-06-25 |
| CN117843768A (zh) | 2024-04-09 |
| CN117843767A (zh) | 2024-04-09 |
| CN114213532B (zh) | 2023-06-13 |
| CN117843771B (zh) | 2024-09-03 |
| CN114213532A (zh) | 2022-03-22 |
| CN117843769B (zh) | 2024-09-03 |
| CN117843767B (zh) | 2024-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110845605B (zh) | 一种抗犬细小病毒的基因工程抗体及其应用 | |
| CN115925895B (zh) | 抗bvdv的纳米抗体及其制备方法及应用 | |
| CN110221065B (zh) | 一种禽滑液囊支原体间接elisa检测试剂盒 | |
| CN108892723B (zh) | 用于检测猪流行性腹泻病毒的单域重链抗体、制备方法及应用 | |
| CN111518174B (zh) | 优化的非洲猪瘟CD2v蛋白及其高效表达方法和应用 | |
| CN114736292B (zh) | 靶向诺如病毒蛋白的纳米抗体及其应用 | |
| CN117843766B (zh) | 高亲和力的抗鸡传染性法氏囊病毒的scFv抗体的制备及其应用 | |
| CN110373393B (zh) | 一种分泌抗传染性法氏囊病毒vp2蛋白单克隆抗体的杂交瘤细胞株1h6 | |
| CN101921800B (zh) | 启动因子作为融合标签的大肠杆菌蛋白表达载体及其构建方法和应用 | |
| CN116375889B (zh) | 狂犬病病毒糖蛋白抗原、截短体及其应用 | |
| CN108982847B (zh) | 一种导致鸭脾脏坏死的鸭呼肠孤病毒的间接elisa检测方法 | |
| CN108693357B (zh) | 一种检测新型鸡呼肠孤病毒抗体的间接elisa检测试剂盒及应用 | |
| Salgado et al. | Homology between two different Salmonella phages: Salmonella enterica serovar Typhimurium phage P22 and Salmonella enterica serovar Anatum var. 15+ phage ε34 | |
| CN117924470B (zh) | 一种靶向甲型流感病毒核蛋白纳米抗体的制备方法和应用 | |
| CN117487009B (zh) | 抗鸡pml单克隆抗体及其应用 | |
| CN114106170B (zh) | 一种抗大田软海绵酸单链抗体的氨基酸序列及其表达载体 | |
| CN113087790B (zh) | 抗非洲猪瘟p72蛋白单域抗体及应用 | |
| CN116462743B (zh) | 鲍曼不动杆菌翻译延伸因子重组蛋白、制备方法及应用 | |
| CN110376385B (zh) | 一种基因工程表达qx型鸡传染性支气管炎病毒s1蛋白抗原的制备方法与应用 | |
| CN116804196A (zh) | 一种用于检测hcmv病毒的核酸适配体、试剂盒及应用 | |
| Mukantayev et al. | OBTAINING STRAIN-PRODUCER OF RECOMBINANT HEXON OF BOVINE ADENOVIRUS TYPE 3 | |
| RU2073719C1 (ru) | Фрагмент днк нс 250, полученный с помощью химического синтеза, рекомбинантный полипептид нс 250 молекулярной массы 120 - 130 кда, обладающий способностью связывать антитела к продукту гена белка ns3 вируса гепатита с, полученный при культивировании штамма бактерий escherichia coli и штамм бактерий escherichia coli - продуцент рекомбинантного полипептида нс 250, обладающего способностью связывать антитела к продукту гена белка ns3 вируса гепатита с | |
| CN116333106A (zh) | 一种黄曲霉毒素b1抗体及应用 | |
| CN115785288A (zh) | 一种小反刍兽疫病毒h-n的抗原表位融合蛋白及其应用 | |
| CN113214364A (zh) | 一种多重耐药鲍曼不动杆菌识别元件的挖掘与验证 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |